Shares of Dr. Martens plc (LON:DOCS - Get Free Report) fell 0% on Tuesday . The stock traded as low as GBX 61.70 and last traded at GBX 62.69. 959,172 shares were traded during mid-day trading, a decline of 93% from the average session volume of 13,322,682 shares. The stock had previously closed at GBX 62.70.
Analyst Upgrades and Downgrades
DOCS has been the subject of a number of recent analyst reports. Royal Bank Of Canada reissued a "sector perform" rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Berenberg Bank reissued a "buy" rating on shares of Dr. Martens in a report on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 6,000.
Read Our Latest Analysis on DOCS
Dr. Martens Stock Down 0.0%
The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 120.66. The company has a market cap of £605.98 million, a P/E ratio of 36.88, a price-to-earnings-growth ratio of 6.40 and a beta of 0.20. The company has a fifty day moving average of GBX 66.75 and a 200 day moving average of GBX 77.78.
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.